Published in Circulation on February 23, 2010
Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One (2014) 1.35
The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study. BMC Cardiovasc Disord (2011) 0.81
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol (2010) 0.80
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Sick individuals and sick populations. Int J Epidemiol (1985) 23.44
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med (2008) 18.34
Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med (2007) 16.95
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol (2004) 12.03
Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) (1981) 11.00
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med (2004) 10.35
Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA (2004) 9.99
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet (1986) 7.35
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 4.71
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med (2009) 4.19
C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 3.50
Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol (2008) 3.33
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J (1978) 3.19
The things to come of SHAPE: cost and effectiveness of cardiovascular prevention. Am J Cardiol (2007) 2.60
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf (2009) 2.18
Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol (2008) 2.14
Variation in event rates in trials of patients with type 2 diabetes. JAMA (2009) 2.08
Identifying and addressing safety signals in clinical trials. N Engl J Med (2008) 1.58
Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab (2001) 1.49
The efficacy of combining several risk factors as a screening test. J Med Screen (2005) 1.34
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 1.23
Discarding logic: 2008 Ancel Keys Memorial Lecture. Circulation (2009) 0.90
Ancel Keys Lecture. Circulation (1991) 0.87
Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? JAMA (2008) 0.87
Introduction to Ancel Keys Lecture. Ancel Keys, pioneer. Circulation (1991) 0.82
Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol (2009) 0.81
Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. Int J Epidemiol (2009) 0.77
Preliminary observations from preliminary trial results: have we finally had enough? Circ Cardiovasc Qual Outcomes (2008) 0.76